XBiotech (XBIT) Stock Forecast, Price & News

XBiotech's stock was trading at $3.51 at the start of the year. Since then, XBIT stock has increased by 55.8% and is now trading at $5.47.
View the best growth stocks for 2023 here.

XBiotech saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 83,800 shares, an increase of 23.1% from the April 30th total of 68,100 shares. Based on an average trading volume of 67,700 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.5% of the company's stock are sold short.
View XBiotech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 30th 2023.
View our XBIT earnings forecast.

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.25%), Connor Clark & Lunn Investment Management Ltd. (0.19%), Two Sigma Investments LP (0.18%), Renaissance Technologies LLC (0.17%), Two Sigma Advisers LP (0.16%) and Susquehanna International Group LLP (0.13%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends.

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XBIT stock can currently be purchased for approximately $5.47.

XBiotech (NASDAQ:XBIT) has a market capitalization of $166.51 million and generates $4.01 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.